Viva Biotech and BioMap Reached a Strategic Collaboration Agreement, To Jointly Accelerate the Early Drug Discovery through AI Technology
News provided by
Share this article
Share this article
SHANGHAI, May 10, 2021 /PRNewswire/ Hosted by BioMap and Adock, the first generation of China Biocomputing Conference was successfully launched in Suzhou. The conference is aiming to unite with biotech and IT industry partners to create a multi-party integrated industrial ecosystem, and realize AI s comprehensive empowerment in the field of biotechnology.
Viva Biotech was invited to attend the conference, and announced a strategic collaboration agreement with BioMap. This collaboration will be based on the AI + biological computing engine from BioMap, with the structure-based drug discovery platform from Viva Biotech, to jointly accelerate the R & D of the novel drugs.
Search jobs Accelerating Innovation, Deepening Integration | Viva Biotech Online Investor Day Review
SHANGHAI, Dec. 13, 2020 /PRNewswire/ Viva Biotech s Online Investor Day was successfully hosted on December 8, 2020. The management team conducted an online dialogue with nearly 400 investors, focusing on the company s strategy, personnel plans, technology platforms, integration strategic plans, investment incubation, and more.
Dr. Chen Mao, Chairman and CEO of Viva Biotech, shared the market potential for CRO and CDMO companies, as well as the four major trends of the CXO industry. Dr. Mao also elaborated the innovative two-wheel driven business model of Viva Biotech that covers the CFS (Cash for Service) + EFS (Equity for Service). Along with the integration and expansion of the CFS business through the industrial chain and the continued growth of the EFS portfolio, Viva will continue adhering to their mission of becoming a cradle for innovative biote